Ultra-LEAF™ Purified anti-human IFN-γ Antibody

Product Details

Verified Reactivity

Human

Reported Reactivity

Chimpanzee, Baboon, Cynomolgus, Rhesus, African Green, Pigtailed Macaque, Sooty Mangabey

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

E. coli-expressed recombinant human IFN-γ

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.

Endotoxin Level

Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

ICFC - Quality tested
FC, Neut - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Flow Cytometry²: The fluorochrome-labeled B27 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-? -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.
Neutralization^1,3,6,7: The Ultra-LEAF™ Purified antibody (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IFN-? bioactivity (Cat. No. 506531).

Application References

1. Favre C, et al. 1989. Molec. Immunol. 26:17. (Neut)
2. Kaur A, et al. 2002. J Virol. 76:3646.
3. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut)
4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag.
5. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
6. Acosta-Rodriguez EV, et al. 2007. Nat. Immunol. 9:942-9. (Neut)
7. Gangur V, et al. 1998. FASEB J. 12:705-13. (Neut)

Product Citations

1. Asashima H, et al. 2023. Cell Rep. 42:111895. PubMed
2. Gruber CN, et al. 2020. Cell. 183:982. PubMed
3. Bhojnagarwala PS, et al. 2022. Mol Ther Oncolytics. 26:289. PubMed
4. OConnor RA, et al. 2021. OncoImmunology. 10(1):1940675. PubMed
5. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed

RRID

AB_2801091 (BioLegend Cat. No. 506531)
AB_2801091 (BioLegend Cat. No. 506532)
AB_2801091 (BioLegend Cat. No. 506533)
AB_2801091 (BioLegend Cat. No. 506534)
AB_2801091 (BioLegend Cat. No. 506535)
AB_2801091 (BioLegend Cat. No. 506536)

Antigen Details

Structure

Cytokine; dimer; 20-25 kD (Mammalian)

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC

Cell Sources

CD8⁺ and CD4⁺ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2

Gene ID

3458 View all products for this Gene ID

UniProt

View information about IFN-gamma on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

Certificate of Analysis